pJEP303-pAAV-CMV-dSaCas9-VP64-pA
(Plasmid
#113678)
-
PurposeA CMV driven de-catalyzed SaCas9 fused to VP64 domain for increased transcription in targeted region
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 113678 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneAAV
-
Backbone manufacturerAlligent Technologies
- Backbone size w/o insert (bp) 3619
- Total vector size (bp) 7073
-
Vector typeAAV, CRISPR, Synthetic Biology
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namede-catalyzed SaCas9
-
SpeciesSynthetic
-
Tags
/ Fusion Proteins
- VP64 (C terminal on insert)
- NLS (N terminal on insert)
- NLS (C terminal on insert)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byGeorge Church, AAV_NLS-dSaCas9-NLS-VPR plasmid #68495
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pJEP303-pAAV-CMV-dSaCas9-VP64-pA was a gift from Jonathan Ploski (Addgene plasmid # 113678 ; http://n2t.net/addgene:113678 ; RRID:Addgene_113678) -
For your References section:
The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase. Kumar N, Stanford W, de Solis C, Aradhana, Abraham ND, Dao TJ, Thaseen S, Sairavi A, Gonzalez CU, Ploski JE. Front Mol Neurosci. 2018 Nov 13;11:413. doi: 10.3389/fnmol.2018.00413. eCollection 2018. 10.3389/fnmol.2018.00413 PubMed 30483052